ORMP

Oramed Pharmaceuticals Inc.
CAPPED RATING

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

Oramed Pharmaceuticals Inc. (ORMP) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Growth (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
B+
Factor Score 3.8 / 5.0
Growth
D-
Factor Score 0.8 / 5.0
Profitability
C
Factor Score 2.4 / 5.0
Momentum
C+
Factor Score 2.7 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 1.0
EV / EBITDA -6.8
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -18.8%
Price Return 12M 61.1%
Catalyst Signal 0.00
Market Cap $151.8M
TTM Revenue $0.0
Price / Sales N/A
ROE 53.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 B+ (3.8) D- (0.8) C (2.4) C+ (2.7) C+ (2.6) C (2.5)
2026-11-07 B+ (3.8) A+ (5.0) C (2.3) B- (3.1) C+ (2.7) B (3.4)
2026-10-31 A- (3.9) A+ (5.0) C (2.3) B- (3.1) C+ (2.7) B (3.4)
2026-10-24 B+ (3.8) A+ (5.0) C (2.3) B (3.2) C+ (2.6) B (3.4)
2026-10-17 B+ (3.7) A+ (5.0) C (2.3) B (3.2) C+ (2.6) B (3.4)
Page 1 of 4